Patient-reported outcomes in HIV clinical trials evaluating antiretroviral treatment: a systematic review

References

• Ahmed, S., Berzon, R. A., Revicki, D. A., Lenderking, W. R., Moinpour, C. M., Basch, E., Reeve, B. B., & Wu, A. W. (2012). The use of patient-reported outcomes (PRO) within comparative effectiveness research: Implications for clinical practice and health care policy. Medical Care, 50(12), 1060–1070. https://doi.org/10.1097/MLR.0b013e318268aaff
   PubMed Web of Science ®Google Scholar
• Arribas, J. R., DeJesus, E., van Lunzen, J., Zurawski, C., Doroana, M., Towner, W., Lazzarin, A., Nelson, M., McColl, D., Andreatta, K., Swamy, R., Szwarcberg, J., & Nguyen, T. (2017). Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-PI. HIV Clinical Trials, 18(3), 118–125. https://doi.org/10.1080/15284336.2017.1330440
   PubMed Web of Science ®Google Scholar
• Brunetta, J., Moreno Guillén, S., Antinori, A., Yeni, P., Wade, B., Johnson, M., Shalit, P., Ebrahimi, R., Johnson, B., Walker, I., & De-Oertel, S. (2015). Patient-reported outcomes after a switch to a single-tablet regimen of rilpivirine, emtricitabine, and tenofovir DF in HIV-1-positive, virologically suppressed individuals: additional findings from a randomized, open-label, 48-week trial. The Patient - Patient-Centered Outcomes Research, 8(3), 257–267. https://doi.org/10.1007/s40271-015-0123-2
   Web of Science ®Google Scholar
• Bucciardini, R., Wu, A. W., Floridia, M., Fragola, V., Ricciardulli, D., Tomino, C., Weimer, L. E., Pirillo, M. F., Mirra, M., Marzi, M., Giannini, G., Galluzzo, C. M., Andreotti, M., Massella, M., & Vella, S. (2000). Quality of life outcomes of combination zidovudine–didanosine–nevirapine and zidovudine–didanosine for antiretroviral-naive advanced HIV-infected patients. AIDS (London, England), 14(16), 2567–2574. https://doi.org/10.1097/00002030-200011100-00020
   PubMed Web of Science ®Google Scholar
• Cahn, P., Montaner, J., Junod, P., Patterson, P., Krolewiecki, A., Andrade-Villanueva, J., Cassetti, I., Sierra-Madero, J., Casiró, A. D., Bortolozzi, R., Lupo, S. H., Longo, N., Rampakakis, E., Ackad, N., Sampalis, J. S., & Landay, A. (2011). Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1st PI-based regimen. PLoS ONE, 6(8), https://doi.org/10.1371/journal.pone.0023726
   Google Scholar
• Campo, R. E., Cohen, C., Grimm, K., Shangguan, T., Maa, J., & Seekins, D. (2010). Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients. International Journal of STD & AIDS, 21(3), 166–171. https://doi.org/10.1258/ijsa.2009.008487
   PubMed Web of Science ®Google Scholar
• Chan, P., Kroon, O., Colby, D., Sacdalan, C., Pinyakorn, S., Tipsuk, S., Chomchey, N., Phanuphak, N., Phanuphak, P., Ananworanich, J., Valcour, V., Spudich, S., Paul, R., & on behalf of RV254/SEARCH 010 Research Team (2019). Neuropsychiatric outcomes before and after switching to Dolutegravir (DTG)-based therapy. CROI 2019.
   Google Scholar
• Chatterton, M., Scott-Lennox, J., Wu, A., & Scott, J. (1999). Quality of life and treatment satisfaction after the addition of Lamivudine or Lamivudine plus loviride to Zidovudine-containing regimens in treatment-experienced patients with HIV infection. PharmacoEconomics, 15(Supplement 1), 67–74. https://doi.org/10.2165/00019053-199915001-00006
   PubMedGoogle Scholar
• Cingolani, A., Romaine, J., Tavelli, A., Maggiolo, F., Camici, M., Bai, F., Rusconi, S., Cattelan, A. M., Antinori, A., Cauda, R., & Monforte, A. (2019). Well-being in people living with HIV/AIDS (PLWHA) according to cART exposure: Data from IOCONA cohort. EACS 2019.
   Google Scholar
• Cohen, C., Revicki, D. A., Nabulsi, A., Sarocco, P. W., & Jiang, P. (1998). A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. AIDS (London, England), 12(12), 1495–1502. https://doi.org/10.1097/00002030-199812000-00012
   PubMed Web of Science ®Google Scholar
• Cooper, V., Moyle, G. J., Fisher, M., Reilly, G., Ewan, J., Liu, H. C., Horne, R., & for the SWEET (Simplification With Easier Emtricitabine Tenofovir) group, UK. (2011). Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz. AIDS Care, 23(6), 705–713. https://doi.org/10.1080/09540121.2010.534433
   PubMed Web of Science ®Google Scholar
• Dejesus, E., Young, B., Morales-Ramirez, J. O., Sloan, L., Ward, D. J., Flaherty, J. F., Ebrahimi, R., Maa, J. F., Reilly, K., Ecker, J., & McColl, D. (2009). AI266073 study group simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. JAIDS Journal of Acquired Immune Deficiency Syndromes, 51(2), 163–174. https://doi.org/10.1097/QAI.0b013e3181a572cf
   PubMed Web of Science ®Google Scholar
• Delate, T., & Coons, S. J. (2000). The discriminative ability of the 12-item short form health survey (SF-12) in a sample of persons infected with HIV. Clinical Therapeutics, 22(9), 1112–1120. https://doi.org/10.1016/S0149-2918(00)80088-0
   PubMed Web of Science ®Google Scholar
• Eaton, E., Gravett, R., Tamhane, A., & Mugavero, M. (2019). ART initiation, regardless of regimen, is associated with improvement in self-reported depression. CROI 2019.
   Google Scholar
• Emuren, L., Welles, S., Polansky, M., Evans, A. A., Macalino, G., Agan, B. K., & Infectious Disease Clinical Research Program HIV Working Group. (2018). Lower health-related quality of life predicts all-cause hospitalization among HIV-infected individuals. Health and Quality of Life Outcomes, 16(1), 107. https://doi.org/10.1186/s12955-018-0931-x
   PubMedGoogle Scholar
• Engler, K., Lenart, A., Lessard, D., Toupin, I., & Lebouche, B. (2018). Barriers to antiretroviral therapy adherence in developed countries: A qualitative synthesis to develop a conceptual framework for a new patient-reported outcome measure. AIDS Care, 30(sup1), 17–28. https://doi.org/10.1080/09540121.2018.1469725
   PubMed Web of Science ®Google Scholar
• Engler, K., Lessard, D., & Lebouche, B. (2017). A review of HIV-specific patient-reported outcome measures. The Patient, 10(2), 187–202. https://doi.org/10.1007/s40271-016-0195-7
   PubMedGoogle Scholar
• Fumaz, C. R., Tuldra, A., Ferrer, M. J., Paredes, R., Bonjoch, A., Jou, T., Negredo, E., Romeu, J., Sirera, G., Tural, C., & Clotet, B. (2002). Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. JAIDS-HAGERSTOWN MD, 29(3), 244–253. https://doi.org/10.1097/00042560-200203010-00004
   Google Scholar
• Gnanasakthy, A., Mordin, M., Evans, E., Doward, L., & DeMuro, C. (2017). A review of patient-reported outcome labeling in the United States (2011-2015). Value in Health, 20(3), 420–429. https://doi.org/10.1016/j.jval.2016.10.006
   PubMed Web of Science ®Google Scholar
• Greenhalgh, J., Gooding, K., Gibbons, E., Dalkin, S., Wright, J., Valderas, J., & Black, N. (2018). How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? A realist synthesis. Journal of Patient-Reported Outcomes, 2(1), 42. https://doi.org/10.1186/s41687-018-0061-6
   PubMedGoogle Scholar
• Hodder, S. L., Mounzer, K., DeJesus, E., Ebrahimi, R., Grimm, K., Esker, S., Ecker, J., Farajallah, A., & Flaherty, J. F. (2010). Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care and STDs, 24(2), 87–96. https://doi.org/10.1089/apc.2009.0259
   PubMed Web of Science ®Google Scholar
• Holzemer, W. L., Gygax Spicer, J., Skodol Wilson, H., Kemppainen, J. K., & Coleman, C. (1998). Validation of the quality of life scale: Living with HIV. Journal of Advanced Nursing, 28(3), 622–630. https://doi.org/10.1046/j.1365-2648.1998.00800.x
   PubMed Web of Science ®Google Scholar
• Justice, A. C., Holmes, W., Gifford, A. L., Rabeneck, L., Zackin, R., Sinclair, G., Weissman, S., Neidig, J., Marcus, C., Chesney, M., Cohn, S. E., & Wu, A. W. (2001). Development and validation of a self-completed HIV symptom index. Journal of Clinical Epidemiology, 54(12 SUPPL. 1), S77–S90. https://doi.org/10.1016/S0895-4356(01)00449-8
   PubMedGoogle Scholar
• Justice, A. C., Rabeneck, L., Hays, R. D., Wu, A. W., & Bozzette, S. A. (1999). Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: A comparison with self-reported symptoms. Outcomes Committee of the AIDS clinical trials Group. Journal of Acquired Immune Deficiency Syndromes, 21(2), 126–133.
   PubMed Web of Science ®Google Scholar
• Kelly, C., Kall, M., Croxford, S., & Delpech, V. (2019, April 2–5). Association of side effects to health-related quality of life: A population study of people living with HIV in England and Wales. 25th Annual Conference of BHIVA, Bournemouth International Centre, UK.
   Google Scholar
• Kjaer, A., Rasmussen, T. A., Hjollund, N. H., Rodkjaer, L. O., & Storgaard, M. (2018). Patient-reported outcomes in daily clinical practise in HIV outpatient care. International Journal of Infectious Diseases, 69, 108–114. https://doi.org/10.1016/j.ijid.2018.02.015
   PubMed Web of Science ®Google Scholar
• Kleijnen, S., Leonardo Alves, T., Meijboom, K., Lipska, I., De Boer, A., Leufkens, H. G., & Goettsch, W. G. (2017). The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries. Quality of Life Research, 26(9), 2479–2488. https://doi.org/10.1007/s11136-017-1574-9
   PubMed Web of Science ®Google Scholar
• Kozak, M. S., Mugavero, M. J., Ye, J., Aban, I., Lawrence, S. T., Nevin, C. R., Raper, J. L., McCullumsmith, C., Schumacher, J. E., Crane, H. M., Kitahata, M. M., Saag, M. S., & Willig, J. H. (2012). Patient reported outcomes in routine care: Advancing data capture for HIV cohort research. Clinical Infectious Diseases, 54(1), 141–147. https://doi.org/10.1093/cid/cir727
   PubMed Web of Science ®Google Scholar
• Mathews, W. C., & May, S. (2007). Euroqol (EQ-5D) measure of quality of life predicts mortality, emergency department utilization, and hospital discharge rates in HIV-infected adults under care. Health and Quality of Life Outcomes, 5(1), 5. https://doi.org/10.1186/1477-7525-5-5
   PubMedGoogle Scholar
• Mora-Peris, B., Else, L., Vera, J., Penchala, S. D., Petersen, C., Khan, M., Toniolo, S., Cercignani, M., Keegan, M., Khoo, S., & Winston, S. (2019). Cerebral Function parameters in people living with HIV switching integrase inhibitor. CROI 2019.
   Google Scholar
• Murray, M. I., Markowitz, M., Frank, I., Grant, R. M., Mayer, K. H., Hudson, K. J., Stancil, B. S., Ford, S. L., Patel, P., Rinehart, A. R., Spreen, W. R., & Margolis, D. A. (2018). Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. HIV Clinical Trials, 19(4), 129–138. https://doi.org/10.1080/15284336.2018.1511346
   PubMed Web of Science ®Google Scholar
• Nachman, S., Alvero, C., Teppler, H., Homony, B., Rodgers, A. J., Graham, B. L., Fenton, T., Frenkel, L. M., Browning, R. S., Hazra, R., Wiznia, A. A., Acosta, E., Douglas, S., Fry, C., Kuryla, S., Perdue, L., Samson, P., Spector, S., Toye, M., … Zheng, N. (2018). Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: A phase 1/2 open label, non-randomised, multicentre trial. The Lancet HIV, 5(12), e715–e722. https://doi.org/10.1016/S2352-3018(18)30257-1
   PubMed Web of Science ®Google Scholar
• Pasquau, J., Hidalgo-Tenorio, C., Montes, M. L., Romero-Palacios, A., Vergas, J., Sanjoaquín, I., Hernández-Quero, J., Aguirrebengoa, K., Orihuela, F., Imaz, A., Ríos-Villegas, M. J., Flores, J., Fariñas, M. C., Vázquez, P., Galindo, M. J., García-Mercé, I., Lozano, F., de los Santos, I., de Jesus, S. E., … Winston, A. (2018). High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial. PLoS ONE, 13(4), https://doi.org/10.1371/journal.pone.0195068
   Google Scholar
• Pinheiro, L. C., Zagar, T. M., & Reeve, B. B. (2017). The prognostic value of pre-diagnosis health-related quality of life on survival: A prospective cohort study of older Americans with lung cancer. Quality of Life Research, 26(7), 1703–1712. https://doi.org/10.1007/s11136-017-1515-7
   PubMed Web of Science ®Google Scholar
• Pozniak, A., Flamm, J., Antinori, A., Bloch, M., Ward, D., Berenguer, J., Cote, P., Andreatta, K., Garner, W., Szwarcberg, J., Nguyen-Cleary, T., McColl, D. J., & Piontkowsky, D. (2017). Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. HIV Clinical Trials, 18(4), 141–148. https://doi.org/10.1080/15284336.2017.1338844
   PubMed Web of Science ®Google Scholar
• Schönnesson, L. N., Ross, M. W., & Williams, M. (2004). The HIV medication Self-Reported Nonadherence Reasons (SNAR) index and its underlying psychological dimensions. AIDS and Behavior, 8(3), 293–301. https://doi.org/10.1023/B:AIBE.0000044076.98833.64
   PubMed Web of Science ®Google Scholar
• Shahriar, J., Delate, T., Hays, R. D., & Coons, S. J. (2003). Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease. Health and Quality of Life Outcomes, 1(1), 25. https://doi.org/10.1186/1477-7525-1-25
   PubMedGoogle Scholar
• Shubber, Z., Mills, E. J., Nachega, J. B., Vreeman, R., Freitas, M., Bock, P., Nsanzimana, S., Penazzato, M., Appolo, T., Doherty, M., Ford, N., & Weiser, S. D. (2016). Patient-reported barriers to adherence to antiretroviral therapy: A systematic review and Meta-analysis. PLOS Medicine, 13(11), e1002183. https://doi.org/10.1371/journal.pmed.1002183
   PubMed Web of Science ®Google Scholar
• Simpson, K. N., Hanson, K. A., Harding, G., Haider, S., Tawadrous, M., Khachatryan, A., Pashos, C. L., & Wu, A. W. (2013). Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: A 10-year review. Health and Quality of Life Outcomes, 11(1), 164. https://doi.org/10.1186/1477-7525-11-164
   PubMedGoogle Scholar
• Spire, B., Arnould, B., Barbier, F., Durant, J., Gilquin, J., Landman, R., Carret, S., Saussier, C., El Kebir, S., & Cohen-Codar, I. (2009). Simplification and first validation of a short battery of patient questionnaires for clinical management of HIV-infected patients: The HIV-SQUAD (Symptom Quality of life Adherence) Questionnaire. HIV Clinical Trials, 10(4), 215–232. https://doi.org/10.1310/hct1004-215
   PubMed Web of Science ®Google Scholar
• Sprinz, E., Neto, J. A., Bargman, E., Green, S. L., Luo, M. P., Sylte, J. R., McMillan, F. I., King, K. R., Rode, R. A., Brun, S. C., Hanna, G. J., & Podsadecki, T. J. (2006). Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy. HIV Clinical Trials, 7(6), 291–308. https://doi.org/10.1310/hct0706-291
   PubMed Web of Science ®Google Scholar
• Toupin, I., Engler, K., Lessard, D., Wong, L., Lènàrt, A., Spire, B., Raffi, F., & Lebouché, B. (2018). Developing a patient-reported outcome measure for HIV care on perceived barriers to antiretroviral adherence: Assessing the needs of HIV clinicians through qualitative analysis. Quality of Life Research, 27(2), 379–388. https://doi.org/10.1007/s11136-017-1711-5
   PubMed Web of Science ®Google Scholar
• van Lunzen, J., Antinori, A., Cohen, C. J., Arribas, J. R., Wohl, D. A., Rieger, A., Rachlis, A., Bloch, M., Segal-Maurer, S., Garner, W., Porter, D., Bosse, M., Piontkowsky, D., Chuck, S. K., & De-Oertel, S. (2016). Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: Week 96 efficacy and safety from a randomized phase 3b study. AIDS (London, England), 30(2), 251–259. https://doi.org/10.1097/QAD.0000000000000911
   PubMed Web of Science ®Google Scholar
• Vera, J., Toniolo, S., Cercignani, M., Mora-Peris, B., Alagaratnam, J., Underwood, J., Boffito, M., Nelson, M., & Winston, A. (2019). Brain connectivity in neurologically asymptomatic people with HIV switching art. CROI 2019.
   Google Scholar
• WHOQOL (World Health Organization's Quality of Life Instrument) HIV Group (2003). Initial steps to developing the World Health Organization's Quality of Life instrument (WHOQOL) module for international assessment in HIV/AIDS. AIDS Care, 15(3), 347–357. https://doi.org/10.1080/0954012031000105405
   PubMed Web of Science ®Google Scholar
• Wilkins, E. L., Cohen, C. J., Trottier, B., Esser, S., Smith, D. E., Haas, B., Brinson, C., Garner, W., Chuck, S., Thorpe, D., & De-Oertel, S. (2016). Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment. AIDS Care, 28(3), 401–408. https://doi.org/10.1080/09540121.2015.1096890
   PubMed Web of Science ®Google Scholar
• Wohl, D., Clarke, A., Maggiolo, F., Garner, W., Laouri, M., Martin, H., & Quirk, E. (2018). Patient-reported symptoms over 48 weeks among participants in randomized, double-blind, phase III non-inferiority trials of adults with HIV on co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus co-formulated abacavir, dolutegravir, and lamivudine. The Patient, 11(5), 561–573. https://doi.org/10.1007/s40271-018-0322-8
   PubMedGoogle Scholar
• Woodcock, A., & Bradley, C. (2006). Validation of the revised 10-item HIV treatment satisfaction questionnaire status version and new change version. Value in Health, 9(5), 320–333. https://doi.org/10.1111/j.1524-4733.2006.00121.x
   PubMed Web of Science ®Google Scholar
• Wu, A. W., Revicki, D. A., Jacobson, D., & Malitz, F. E. (1997). Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Quality of Life Research, 6(6), 481–493. https://doi.org/10.1023/A:1018451930750
   PubMed Web of Science ®Google Scholar
• Wu, A. W., Rubin, H. R., Mathews, W. C., Ware, J. E., Brysk, L. T., Hardy, W. D., Bozzette, S. A., Spector, S. A., & Richman, D. D. (1991 Aug). A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Medical Care, 29(8), 786–798. https://doi.org/10.1097/00005650-199108000-00011
   PubMed Web of Science ®Google Scholar
• Yeh, R. F., Lipman, B. A., Mayberry, C., Miguel, B., Nemecek, J. J., & Gathe, J. C. (2010). Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults. Journal of the International Association of Physicians in AIDS Care, 9(5), 273–277. https://doi.org/10.1177/1545109710374997
   Google Scholar